Request Free Sample ×

Kindly complete the form below to receive a free sample of this Report

* Please use a valid business email

Leading companies partner with us for data-driven Insights

clients tt-cursor
Hero Background

GCC Epilepsy Surgery Market

ID: MRFR/HC/51352-HCR
200 Pages
Rahul Gotadki
Last Updated: February 06, 2026

GCC Epilepsy Surgery Market Research Report By Procedure Type (Respective Surgery, Laser Interstitial Thermal Therapy (LITT)) and By End User (Hospitals & Clinics, Specialty Centers) - Growth & Industry Forecast 2025 To 2035

Share:
Download PDF ×

We do not share your information with anyone. However, we may send you emails based on your report interest from time to time. You may contact us at any time to opt-out.

GCC Epilepsy Surgery Market Infographic
Purchase Options
  1. 1 SECTION I: EXECUTIVE SUMMARY AND KEY HIGHLIGHTS
  2.   1.1 EXECUTIVE SUMMARY
  3.     1.1.1 Market Overview
  4.     1.1.2 Key Findings
  5.     1.1.3 Market Segmentation
  6.     1.1.4 Competitive Landscape
  7.     1.1.5 Challenges and Opportunities
  8.     1.1.6 Future Outlook
  9. 2 SECTION II: SCOPING, METHODOLOGY AND MARKET STRUCTURE
  10.   2.1 MARKET INTRODUCTION
  11.     2.1.1 Definition
  12.     2.1.2 Scope of the study
  13.       2.1.2.1 Research Objective
  14.       2.1.2.2 Assumption
  15.       2.1.2.3 Limitations
  16.   2.2 RESEARCH METHODOLOGY
  17.     2.2.1 Overview
  18.     2.2.2 Data Mining
  19.     2.2.3 Secondary Research
  20.     2.2.4 Primary Research
  21.       2.2.4.1 Primary Interviews and Information Gathering Process
  22.       2.2.4.2 Breakdown of Primary Respondents
  23.     2.2.5 Forecasting Model
  24.     2.2.6 Market Size Estimation
  25.       2.2.6.1 Bottom-Up Approach
  26.       2.2.6.2 Top-Down Approach
  27.     2.2.7 Data Triangulation
  28.     2.2.8 Validation
  29. 3 SECTION III: QUALITATIVE ANALYSIS
  30.   3.1 MARKET DYNAMICS
  31.     3.1.1 Overview
  32.     3.1.2 Drivers
  33.     3.1.3 Restraints
  34.     3.1.4 Opportunities
  35.   3.2 MARKET FACTOR ANALYSIS
  36.     3.2.1 Value chain Analysis
  37.     3.2.2 Porter's Five Forces Analysis
  38.       3.2.2.1 Bargaining Power of Suppliers
  39.       3.2.2.2 Bargaining Power of Buyers
  40.       3.2.2.3 Threat of New Entrants
  41.       3.2.2.4 Threat of Substitutes
  42.       3.2.2.5 Intensity of Rivalry
  43.     3.2.3 COVID-19 Impact Analysis
  44.       3.2.3.1 Market Impact Analysis
  45.       3.2.3.2 Regional Impact
  46.       3.2.3.3 Opportunity and Threat Analysis
  47. 4 SECTION IV: QUANTITATIVE ANALYSIS
  48.   4.1 Healthcare, BY Surgical Procedure Type (USD Million)
  49.     4.1.1 Resective Surgery
  50.     4.1.2 Functional Surgery
  51.     4.1.3 Lesionectomy
  52.     4.1.4 Hemispherectomy
  53.   4.2 Healthcare, BY Indication (USD Million)
  54.     4.2.1 Focal Epilepsy
  55.     4.2.2 Generalized Epilepsy
  56.     4.2.3 Refractory Epilepsy
  57.     4.2.4 Non-Epileptic Seizures
  58.   4.3 Healthcare, BY Patient Age Group (USD Million)
  59.     4.3.1 Pediatric
  60.     4.3.2 Adolescent
  61.     4.3.3 Adult
  62.     4.3.4 Geriatric
  63.   4.4 Healthcare, BY Technology Used (USD Million)
  64.     4.4.1 Neurostimulation Devices
  65.     4.4.2 Surgical Navigation Systems
  66.     4.4.3 Imaging Techniques
  67.     4.4.4 Robotic Surgery
  68.   4.5 Healthcare, BY Post-Surgery Care (USD Million)
  69.     4.5.1 Medication Management
  70.     4.5.2 Rehabilitation Services
  71.     4.5.3 Follow-Up Monitoring
  72.     4.5.4 Psychological Support
  73. 5 SECTION V: COMPETITIVE ANALYSIS
  74.   5.1 Competitive Landscape
  75.     5.1.1 Overview
  76.     5.1.2 Competitive Analysis
  77.     5.1.3 Market share Analysis
  78.     5.1.4 Major Growth Strategy in the Healthcare
  79.     5.1.5 Competitive Benchmarking
  80.     5.1.6 Leading Players in Terms of Number of Developments in the Healthcare
  81.     5.1.7 Key developments and growth strategies
  82.       5.1.7.1 New Product Launch/Service Deployment
  83.       5.1.7.2 Merger & Acquisitions
  84.       5.1.7.3 Joint Ventures
  85.     5.1.8 Major Players Financial Matrix
  86.       5.1.8.1 Sales and Operating Income
  87.       5.1.8.2 Major Players R&D Expenditure. 2023
  88.   5.2 Company Profiles
  89.     5.2.1 Medtronic (US)
  90.       5.2.1.1 Financial Overview
  91.       5.2.1.2 Products Offered
  92.       5.2.1.3 Key Developments
  93.       5.2.1.4 SWOT Analysis
  94.       5.2.1.5 Key Strategies
  95.     5.2.2 Boston Scientific (US)
  96.       5.2.2.1 Financial Overview
  97.       5.2.2.2 Products Offered
  98.       5.2.2.3 Key Developments
  99.       5.2.2.4 SWOT Analysis
  100.       5.2.2.5 Key Strategies
  101.     5.2.3 Johnson & Johnson (US)
  102.       5.2.3.1 Financial Overview
  103.       5.2.3.2 Products Offered
  104.       5.2.3.3 Key Developments
  105.       5.2.3.4 SWOT Analysis
  106.       5.2.3.5 Key Strategies
  107.     5.2.4 Stryker (US)
  108.       5.2.4.1 Financial Overview
  109.       5.2.4.2 Products Offered
  110.       5.2.4.3 Key Developments
  111.       5.2.4.4 SWOT Analysis
  112.       5.2.4.5 Key Strategies
  113.     5.2.5 Abbott Laboratories (US)
  114.       5.2.5.1 Financial Overview
  115.       5.2.5.2 Products Offered
  116.       5.2.5.3 Key Developments
  117.       5.2.5.4 SWOT Analysis
  118.       5.2.5.5 Key Strategies
  119.     5.2.6 NeuroPace (US)
  120.       5.2.6.1 Financial Overview
  121.       5.2.6.2 Products Offered
  122.       5.2.6.3 Key Developments
  123.       5.2.6.4 SWOT Analysis
  124.       5.2.6.5 Key Strategies
  125.     5.2.7 LivaNova (GB)
  126.       5.2.7.1 Financial Overview
  127.       5.2.7.2 Products Offered
  128.       5.2.7.3 Key Developments
  129.       5.2.7.4 SWOT Analysis
  130.       5.2.7.5 Key Strategies
  131.     5.2.8 Natus Medical (US)
  132.       5.2.8.1 Financial Overview
  133.       5.2.8.2 Products Offered
  134.       5.2.8.3 Key Developments
  135.       5.2.8.4 SWOT Analysis
  136.       5.2.8.5 Key Strategies
  137.   5.3 Appendix
  138.     5.3.1 References
  139.     5.3.2 Related Reports
  140. 6 LIST OF FIGURES
  141.   6.1 MARKET SYNOPSIS
  142.   6.2 GCC MARKET ANALYSIS BY SURGICAL PROCEDURE TYPE
  143.   6.3 GCC MARKET ANALYSIS BY INDICATION
  144.   6.4 GCC MARKET ANALYSIS BY PATIENT AGE GROUP
  145.   6.5 GCC MARKET ANALYSIS BY TECHNOLOGY USED
  146.   6.6 GCC MARKET ANALYSIS BY POST-SURGERY CARE
  147.   6.7 KEY BUYING CRITERIA OF HEALTHCARE
  148.   6.8 RESEARCH PROCESS OF MRFR
  149.   6.9 DRO ANALYSIS OF HEALTHCARE
  150.   6.10 DRIVERS IMPACT ANALYSIS: HEALTHCARE
  151.   6.11 RESTRAINTS IMPACT ANALYSIS: HEALTHCARE
  152.   6.12 SUPPLY / VALUE CHAIN: HEALTHCARE
  153.   6.13 HEALTHCARE, BY SURGICAL PROCEDURE TYPE, 2024 (% SHARE)
  154.   6.14 HEALTHCARE, BY SURGICAL PROCEDURE TYPE, 2024 TO 2035 (USD Million)
  155.   6.15 HEALTHCARE, BY INDICATION, 2024 (% SHARE)
  156.   6.16 HEALTHCARE, BY INDICATION, 2024 TO 2035 (USD Million)
  157.   6.17 HEALTHCARE, BY PATIENT AGE GROUP, 2024 (% SHARE)
  158.   6.18 HEALTHCARE, BY PATIENT AGE GROUP, 2024 TO 2035 (USD Million)
  159.   6.19 HEALTHCARE, BY TECHNOLOGY USED, 2024 (% SHARE)
  160.   6.20 HEALTHCARE, BY TECHNOLOGY USED, 2024 TO 2035 (USD Million)
  161.   6.21 HEALTHCARE, BY POST-SURGERY CARE, 2024 (% SHARE)
  162.   6.22 HEALTHCARE, BY POST-SURGERY CARE, 2024 TO 2035 (USD Million)
  163.   6.23 BENCHMARKING OF MAJOR COMPETITORS
  164. 7 LIST OF TABLES
  165.   7.1 LIST OF ASSUMPTIONS
  166.     7.1.1
  167.   7.2 GCC MARKET SIZE ESTIMATES; FORECAST
  168.     7.2.1 BY SURGICAL PROCEDURE TYPE, 2026-2035 (USD Million)
  169.     7.2.2 BY INDICATION, 2026-2035 (USD Million)
  170.     7.2.3 BY PATIENT AGE GROUP, 2026-2035 (USD Million)
  171.     7.2.4 BY TECHNOLOGY USED, 2026-2035 (USD Million)
  172.     7.2.5 BY POST-SURGERY CARE, 2026-2035 (USD Million)
  173.   7.3 PRODUCT LAUNCH/PRODUCT DEVELOPMENT/APPROVAL
  174.     7.3.1
  175.   7.4 ACQUISITION/PARTNERSHIP
  176.     7.4.1

GCC Healthcare Market Segmentation

Healthcare By Surgical Procedure Type (USD Million, 2026-2035)

  • Resective Surgery
  • Functional Surgery
  • Lesionectomy
  • Hemispherectomy

Healthcare By Indication (USD Million, 2026-2035)

  • Focal Epilepsy
  • Generalized Epilepsy
  • Refractory Epilepsy
  • Non-Epileptic Seizures

Healthcare By Patient Age Group (USD Million, 2026-2035)

  • Pediatric
  • Adolescent
  • Adult
  • Geriatric

Healthcare By Technology Used (USD Million, 2026-2035)

  • Neurostimulation Devices
  • Surgical Navigation Systems
  • Imaging Techniques
  • Robotic Surgery

Healthcare By Post-Surgery Care (USD Million, 2026-2035)

  • Medication Management
  • Rehabilitation Services
  • Follow-Up Monitoring
  • Psychological Support

Compare Licence

×
Features License Type
Single User Multiuser License Enterprise User
Price $4,950 $5,950 $7,250
Maximum User Access Limit 1 User Upto 10 Users Unrestricted Access Throughout the Organization
Free Customization
Direct Access to Analyst
Deliverable Format
Platform Access
Discount on Next Purchase 10% 15% 15%
Printable Versions